Biotech · Public company · Bellaire, TX, US
Bio-Path Holdings, Inc.
Ticker BPTH · SEC CIK 0001133818
Track this companyFree. Adds Bio-Path Holdings, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials64 recruiting or active
Pipeline programs12From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline12
- BP1001 (fixed dose)Phase 2 · Chronic Myelogenous Leukemia, Ph1-PositiveClinicalTrials.gov · fetched Nov 12, 2026
- BP1001 (varying dose)Phase 2 · Chronic Myelogenous Leukemia, Ph1-PositiveClinicalTrials.gov · fetched Nov 12, 2026
- BP1001 in combination with Ventoclax plus decitabinePhase 2 · Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- BP1001 plus decitabinePhase 2 · Acute Myeloid Leukemia (AML)ClinicalTrials.gov · fetched Nov 12, 2026
- DasatinibPhase 2 · Chronic Myelogenous Leukemia, Ph1-PositiveClinicalTrials.gov · fetched Nov 12, 2026
- BP1001Phase 1 · Recurrent Adult Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BP1001 in combination with LDACPhase 1 · Recurrent Adult Acute Myeloid LeukemiaClinicalTrials.gov · fetched Nov 12, 2026
- BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxelPhase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- BP1002; Liposomal Bcl-2 Antisense OligodeoxynucleotidePhase 1 · Acute Myeloid Leukemia, in RelapseClinicalTrials.gov · fetched Nov 12, 2026
- Decitabine (in combination with BP1002)Phase 1 · Acute Myeloid Leukemia, in RelapseClinicalTrials.gov · fetched Nov 12, 2026
- L-Bcl-2 antisense oligonucleotidePhase 1 · Mantle Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- BP1001-A in Patients With Advanced or Recurrent Solid TumorsPHASE1 · RECRUITING · started Aug 19, 2022ClinicalTrials.gov NCT04196257 · fetched Nov 12, 2026
- A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)PHASE1 · RECRUITING · started Aug 16, 2022ClinicalTrials.gov NCT05190471 · fetched Nov 12, 2026
- A Clinical Trial of BP1002 in Patients With Advanced Lymphoid MalignanciesPHASE1 · ACTIVE_NOT_RECRUITING · started Nov 5, 2020ClinicalTrials.gov NCT04072458 · fetched Nov 12, 2026
- Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDSPHASE1_PHASE2 · WITHDRAWN · started Sep 1, 2017ClinicalTrials.gov NCT02923986 · fetched Nov 12, 2026
- Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AMLPHASE2 · RECRUITING · started May 1, 2016ClinicalTrials.gov NCT02781883 · fetched Nov 12, 2026
- Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDSPHASE1 · COMPLETED · started Jun 1, 2010ClinicalTrials.gov NCT01159028 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Jul 16, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed May 26, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed May 20, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Mar 20, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Feb 24, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Jan 13, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 29, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 14, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Aug 13, 2025 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 24, 2025 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 15, 2025 · fetched Nov 12, 2026